Results 101 to 110 of about 26,368 (251)

Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient [PDF]

, 2017
Background: Pancreatic cancer occurs more frequently in older patients, but these are underrepresented in the phase III clinical studies that established the current treatment standards. This leads to uncertainty regarding the treatment of older patients
Berger, Anne Katrin, Byl, Anne, Ehmann, Martin, Haag, Georg Martin, Jäger, Dirk, Springfeld, Christoph   +5 more
core   +1 more source

Preoperative Gemcitabine/Nab‐Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative Chemoradiation Therapy Using Gemcitabine Alone

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Although NCCN guidelines recommend preoperative therapy for borderline resectable pancreatic cancer (BR‐PC), it is still unclear which regimen is better. The study objective was to elucidate the prognostic significance of neoadjuvant chemoradiotherapy (NACRT) with gemcitabine/nab‐paclitaxel (GnP‐RT) compared to gemcitabine alone ...
Hirofumi Akita, Hidenori Takahashi, Yousuke Mukai, Masahiko Kubo, Shinichiro Hasegawa, Masayoshi Yasui, Takeshi Omori, Hiroshi Miyata, Hiroshi Wada, Kunihito Gotoh   +9 more
wiley   +1 more source

Metabolic Dependencies in Pancreatic Cancer. [PDF]

, 2018
Pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer with a long-term survival rate under 10%. Available cytotoxic chemotherapies have significant side effects, and only marginal therapeutic efficacy. FDA approved drugs currently used against
Brody, Jonathan R., Vaziri-Gohar, Ali, Winter, Jordan M., Zarei, Mahsa   +3 more
core   +1 more source

Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study [PDF]

, 2014
The optimal sequence of systemic chemotherapy in metastatic breast cancer (MBC) is unknown. We report the case of a woman who was successfully treated with nanoparticle albumin-bound (nab)-paclitaxel for triple negative MBC in our institution.
ARPINO, GRAZIA, DE ANGELIS, CARMINE, DE PLACIDO, SABINO   +2 more
core   +1 more source

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

Annals of Gastroenterological Surgery, EarlyView.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya, Koichi Yagi, Yoshifumi Baba   +2 more
wiley   +1 more source

Towards Protein-Based Viral Mimetics for Cancer Therapies [PDF]

, 2015
High resistance and recurrence rates, along with elevated drug clearance, compel the use of maximum tolerated drug doses in cancer therapy, resulting in high-grade toxicities and limited clinical applicability. Promoting active drug accumulation in tumor
Céspedes, María Virtudes, Ferrer-Miralles, Neus, Mangues, Ramon, Unzueta Elorza, Ugutz, Villaverde Corrales, Antonio, Vázquez Gómez, Esther   +5 more
core   +2 more sources

Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles

Advanced NanoBiomed Research, EarlyView.
This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley   +1 more source

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer [PDF]

, 2013
AIM: To investigate activity, toxicity, and prognostic factors for survival of erlotinib and fixed dose-rate gemcitabine (FDR-Gem) in advanced pancreatic cancer.
Bria, E., Cognetti, F., Gamucci, T., Gelibter, A., Mansueto, G., Milella, M., Moscetti, L., Ruggeri, E. M., Sperduti, I., Vaccaro, V.   +9 more
core   +1 more source

NUAK2 Inhibition Enhances Macromolecular Drug Delivery in a 3D Fibrotic Model of the Pancreatic Tumor Microenvironment

Advanced NanoBiomed Research, EarlyView.
Using a 3D cell culture model of the fibrotic barrier in pancreatic cancer, this work shows that inhibiting NUAK2 kinase in pancreatic stellate cells enhances macromolecular drug delivery. Mechanistically, NUAK2 inhibition disrupted actin stress fiber assembly to downregulate collagen I expression, thus enhancing macromolecular permeability.
Misaki Nakamura, Hiroyoshi Y. Tanaka, Mayu Ohira, Haruko Ohta‐Okano, Reika Nakamura, Yu Seno, Saaya Yara, Sakura Fujita, Daichi Shibata, Masaya Yamamoto, Shinichi Toyooka, Kensuke Osada, Horacio Cabral, Atsushi Masamune, Mitsunobu R. Kano   +14 more
wiley   +1 more source

Effect of intrapleural anti-Vascular Endothelial Growth Factor (VEGF) associated with nab paclitaxel in a murine model of malignant pleural effusion

BMC Cancer
Background Malignant pleural effusion (MPE) is a disease associated with poor prognosis, high morbidity, and significant mortality. Murine models of MPE have successfully replicated its formation and metastases, providing valuable insights into potential
Carlos Sergio Rocha Silva, Lisete Ribeiro Teixeira, Karina Rocha Pereira, Philippe Figueiredo Braga Colares, Vanessa Adelia Alvarenga, Roberta Karla Barbosa Sales, Amanda Cabral Roque, Evaldo Marchi, Ronei Luciano Mamoni, Milena Marques Pagliarelli Acencio   +9 more
doaj   +1 more source